摘要
目的比较氨磺必利与利培酮治疗首发精神分裂症的疗效及安全性。方法将82例首发精神分裂症患者按照随机数字表法分为两组，观察组给予氨磺必利治疗，对照组给予利培酮治疗。观察8周。于治疗前后采用阳性与阴性症状量表评定临床疗效，国际医学组织理事会推荐的分级标准统计不良反应发生率。结果治疗2周末起两组阳性与阴性症状量表总分均较治疗前显著降低（P〈0．01）；同期两组间比较，治疗前差异无显著性（P〉0．05），治疗后观察组显著低于对照组（P〈0．05）。观察组不良反应发生率为20．5％，对照组为45．0％，观察组垃著低于对照组（P〈0．01）。结论氨磺必利治疗首发精神分裂症疗效显著，安全性高，优于利培酮治疗。
Objective To compare the efficacy and safety of amisulpride and risperidone in the treatment of first-episode schizophrenia. Methods Eighty-two first-episode schizophrenics were assigned to two groups according to random number table, observation group was treated with amisulpride, and control group with risperidone for 8 weeks. Efficacies were assessed with the Positive and Negative Syndrome Scale （PANSS） before and after treatment and the incidences of adverse reactions counted according to grading criteria recommended by the Council for International Organizations of Medical Sciences. Results Since the end of the 2^nd week treatment the total PANSS scores of both groups lowered more significantly compared with pretreatment （P 〈 0.01） ; pretreatment group differences weren＇t significant （P〉 0.05 ） and those were significantly lower in observation than in control group （P〈0.05）. The incidence of ad verse reactions was respectively 20.5 % in observation and 45.0% in control group and the former significantly lower than the latter （P〈0.01）. Conclusion Amisulpride has an evident effect and higher safety compared with risperidone in first-episode schizophrenia.
出处
《临床心身疾病杂志》
CAS
2017年第2期48-49,55,共3页
Journal of Clinical Psychosomatic Diseases
